Why Might Cassava Succeed With Its Alzheimer’s Drug, When So Many Have Failed?
Cassava Sciences(NASDAQ:SAVA) is like any other unprofitable biotech — it has a drug in clinical trials, and its investors are hoping the drug works so they can make a lot of money. What makes Cassava really interesting is that it’s zigging where Big Pharma…
